Study Summary
Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect of anti-CD19 CAR-T cells in clinical trials.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD19 CAR-T Cells InjectionBIOLOGICAL
Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Kunming Yan'an Hospital | Kunming | Yunnan | China |